Docetaxel is a chemotherapeutic agent belonging to the taxane class, widely used in cancer treatment. It works by inhibiting microtubule depolymerization, thereby preventing cell division and inducing apoptosis in cancer cells. Docetaxel is effective against a variety of cancers, including breast, lung, prostate, and gastric cancers. It is administered intravenously under careful medical supervision due to its potent effects. The drug was developed as a semi-synthetic derivative of paclitaxel to improve efficacy and reduce side effects. Docetaxel has become a cornerstone in combination chemotherapy regimens. It helps improve survival rates and reduces tumor progression in many cancer patients. Common side effects include neutropenia, fatigue, and fluid retention, requiring close monitoring. Its development marked a significant advancement in anti-mitotic cancer therapy. Today, docetaxel remains one of the most important drugs in modern oncology.
